克服表皮生长因子受体获得性耐药的策略：肺癌的靶向治疗。

Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer.

机构信息

Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, 02215, USA.

出版信息

Arch Pathol Lab Med. 2012 Oct;136(10):1205-9. doi: 10.5858/arpa.2012-0254-RA.

DOI:10.5858/arpa.2012-0254-RA

PMID:23020725

Abstract

Acquired resistance to targeted therapy in epidermal growth factor receptor (EGFR)-mutant lung cancer represents a valuable model for considering strategies of overcoming different types of cellular resistance mechanisms. Using existing data on resistance in EGFR-mutant lung cancer, this review will discuss 3 basic approaches for overcoming resistance to EGFR-targeted therapies: intensification of EGFR inhibition, combination of EGFR inhibitors with other targeted therapies, and changing to anticancer therapies acting via alternate pathways.

摘要

获得性针对表皮生长因子受体（EGFR）突变型肺癌的靶向治疗耐药是一个有价值的模型，用于考虑克服不同类型细胞耐药机制的策略。利用现有关于 EGFR 突变型肺癌耐药的数据，本文将讨论克服 EGFR 靶向治疗耐药的 3 种基本方法：加强 EGFR 抑制、EGFR 抑制剂与其他靶向治疗联合，以及改用通过其他途径发挥作用的抗癌治疗。